{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:17:19Z","timestamp":1784204239444,"version":"3.55.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-C&T-B-030"],"award-info":[{"award-number":["2021-I2M-C&T-B-030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40265-026-02348-4","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:40:00Z","timestamp":1781152800000},"page":"1325-1338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering"],"prefix":"10.1007","volume":"86","author":[{"given":"Sha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-4364","authenticated-orcid":false,"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"1","key":"2348_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5334\/gh.1154","volume":"17","author":"KK Ray","year":"2022","unstructured":"Ray KK, Ference BA, Severin T, Blom D, Nicholls SJ, Shiba MH, et al. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022;17(1):75.","journal-title":"Glob Heart"},{"issue":"25","key":"2348_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"key":"2348_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117577","volume":"395","author":"A Schmidt-Trucksass","year":"2024","unstructured":"Schmidt-Trucksass A, Lichtenstein AH, von Kanel R. Lifestyle factors as determinants of atherosclerotic cardiovascular health. Atherosclerosis. 2024;395:117577.","journal-title":"Atherosclerosis"},{"issue":"32","key":"2348_CR4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"key":"2348_CR5","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"issue":"25 Suppl 2","key":"2348_CR6","first-page":"S1","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45.","journal-title":"Circulation"},{"issue":"12","key":"2348_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","volume":"15","author":"BB Adhyaru","year":"2018","unstructured":"Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15(12):757\u201369.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2348_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13.","journal-title":"Signal Transduct Target Ther"},{"key":"2348_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108480","volume":"249","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S, Vilstrup JP, Gustafsen C, Glerup S, Weyer K. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249:108480.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"2348_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","volume":"24","author":"N Arnold","year":"2022","unstructured":"Arnold N, Koenig W. PCSK9 inhibitor wars: how does Inclisiran fit in with current monoclonal antibody inhibitor therapy? Considerations for patient selection. Curr Cardiol Rep. 2022;24(11):1657\u201367.","journal-title":"Curr Cardiol Rep"},{"key":"2348_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103270","volume":"84","author":"DKW Yow","year":"2025","unstructured":"Yow DKW, Ang WJ, Yap HJ, Ito S, Liu J, Ko J, et al. Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis. EClinicalMedicine. 2025;84:103270.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2348_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14712598.2025.2508837","volume":"25","author":"XL Tang","year":"2025","unstructured":"Tang XL, Hooper AJ, Burnett JR. An evaluation of recaticimab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2025;25(6):577\u201382.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"2348_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","volume":"22","author":"TH Baryakova","year":"2023","unstructured":"Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387\u2013409.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2348_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/nrcardio.2013.208","volume":"11","author":"TH Tajouri","year":"2014","unstructured":"Tajouri TH, Driver SL, Holmes DR Jr. \u2019Take as directed\u2019--strategies to improve adherence to cardiac medication. Nat Rev Cardiol. 2014;11(5):304\u20137.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2348_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/phar.4635","volume":"45","author":"CL Garwood","year":"2025","unstructured":"Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: a state-of-the-art review. Pharmacotherapy. 2025;45(1):54\u201365.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2348_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","volume":"35","author":"S Ko","year":"2021","unstructured":"Ko S, Jo M, Jung ST. Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering. BioDrugs. 2021;35(2):147\u201357.","journal-title":"BioDrugs"},{"issue":"11","key":"2348_CR17","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","volume":"54","author":"S Ko","year":"2022","unstructured":"Ko S, Park S, Sohn MH, Jo M, Ko BJ, Na JH, et al. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. Exp Mol Med. 2022;54(11):1850\u201361.","journal-title":"Exp Mol Med"},{"issue":"10","key":"2348_CR18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","volume":"39","author":"ES Ward","year":"2018","unstructured":"Ward ES, Ober RJ. Targeting FcRn to generate antibody-based therapeutics. Trends Pharmacol Sci. 2018;39(10):892\u2013904.","journal-title":"Trends Pharmacol Sci"},{"key":"2348_CR19","doi-asserted-by":"crossref","unstructured":"Lamb YN. Recaticimab: First Approval. Drugs 2025;85(8):1067-72.","DOI":"10.1007\/s40265-025-02199-5"},{"issue":"20","key":"2348_CR20","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","volume":"84","author":"Y Sun","year":"2024","unstructured":"Sun Y, Lv Q, Guo Y, Wang Z, Huang R, Gao X, et al. Recaticimab as add-on therapy to statins for nonfamilial hypercholesterolemia: The randomized, phase 3 REMAIN-2 trial. J Am Coll Cardiol. 2024;84(20):2037\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2348_CR21","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","volume":"84","author":"M Xu","year":"2024","unstructured":"Xu M, Wang Z, Zhang Y, Liu Y, Huang R, Han X, et al. Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia: the phase 3 REMAIN-1 randomized trial. J Am Coll Cardiol. 2024;84(20):2026\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"2348_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115880","author":"C Barale","year":"2021","unstructured":"Barale C, Melchionda E, Morotti A, Russo I. PCSK9 biology and its role in atherothrombosis. Int J Mol Sci. 2021;22(11):5880.","journal-title":"Int J Mol Sci"},{"issue":"4223","key":"2348_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1126\/science.174194","volume":"191","author":"MS Brown","year":"1976","unstructured":"Brown MS, Goldstein JL. Receptor-mediated control of cholesterol metabolism. Science. 1976;191(4223):150\u20134.","journal-title":"Science"},{"issue":"4","key":"2348_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","volume":"29","author":"JL Goldstein","year":"2009","unstructured":"Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2348_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1083\/jcb.93.3.523","volume":"93","author":"RG Anderson","year":"1982","unstructured":"Anderson RG, Brown MS, Beisiegel U, Goldstein JL. Surface distribution and recycling of the low density lipoprotein receptor as visualized with antireceptor antibodies. J Cell Biol. 1982;93(3):523\u201331.","journal-title":"J Cell Biol"},{"issue":"3","key":"2348_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0092-8674(77)90022-8","volume":"10","author":"RG Anderson","year":"1977","unstructured":"Anderson RG, Brown MS, Goldstein JL. Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell. 1977;10(3):351\u201364.","journal-title":"Cell"},{"issue":"12","key":"2348_CR27","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/embor.2011.205","volume":"12","author":"P Lo Surdo","year":"2011","unstructured":"Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, et al. Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH. EMBO Rep. 2011;12(12):1300\u20135.","journal-title":"EMBO Rep"},{"issue":"6","key":"2348_CR28","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/febs.12721","volume":"281","author":"J Martinez-Olivan","year":"2014","unstructured":"Martinez-Olivan J, Arias-Moreno X, Velazquez-Campoy A, Millet O, Sancho J. LDL receptor\/lipoprotein recognition: endosomal weakening of ApoB and ApoE binding to the convex face of the LR5 repeat. FEBS J. 2014;281(6):1534\u201346.","journal-title":"FEBS J"},{"issue":"3","key":"2348_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0092-8674(83)90052-1","volume":"32","author":"MS Brown","year":"1983","unstructured":"Brown MS, Anderson RG, Goldstein JL. Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell. 1983;32(3):663\u20137.","journal-title":"Cell"},{"issue":"24","key":"2348_CR30","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","volume":"127","author":"H Tavori","year":"2013","unstructured":"Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, et al. Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127(24):2403\u201313.","journal-title":"Circulation"},{"issue":"28","key":"2348_CR31","doi-asserted-by":"publisher","first-page":"20502","DOI":"10.1074\/jbc.M701634200","volume":"282","author":"TS Fisher","year":"2007","unstructured":"Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem. 2007;282(28):20502\u201312.","journal-title":"J Biol Chem"},{"issue":"3","key":"2348_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5551\/jat.27615","volume":"22","author":"S Li","year":"2015","unstructured":"Li S, Li JJ. PCSK9: a key factor modulating atherosclerosis. J Atheroscler Thromb. 2015;22(3):221\u201330.","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"2348_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161\u20135.","journal-title":"Nat Genet"},{"issue":"12","key":"2348_CR34","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med"},{"issue":"3","key":"2348_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514\u201323.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2348_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","volume":"193","author":"AJ Hooper","year":"2007","unstructured":"Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193(2):445\u20138.","journal-title":"Atherosclerosis"},{"issue":"13","key":"2348_CR37","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s40265-015-0460-4","volume":"75","author":"A Markham","year":"2015","unstructured":"Markham A. Evolocumab: first global approval. Drugs. 2015;75(13):1567\u201373.","journal-title":"Drugs"},{"issue":"14","key":"2348_CR38","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-015-0469-8","volume":"75","author":"A Markham","year":"2015","unstructured":"Markham A. Alirocumab: first global approval. Drugs. 2015;75(14):1699\u2013705.","journal-title":"Drugs"},{"issue":"16","key":"2348_CR39","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s40265-023-01952-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Tafolecimab: first approval. Drugs. 2023;83(16):1545\u20139.","journal-title":"Drugs"},{"key":"2348_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107340","volume":"207","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Pei Z, Chen B, Qu Y, Dong X, Yu B, et al. Ebronucimab in Chinese patients with hypercholesterolemia\u2013-a randomized double-blind placebo-controlled Phase 3 trial to evaluate the efficacy and safety of ebronucimab. Pharmacol Res. 2024;207:107340.","journal-title":"Pharmacol Res"},{"issue":"9","key":"2348_CR41","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.numecd.2024.04.011","volume":"34","author":"W Zhao","year":"2024","unstructured":"Zhao W, Cheng Z, Ji X, Pei Z, Yang K, Huang Z, et al. Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia. Nutr Metab Cardiovasc Dis. 2024;34(9):2217\u201325.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"19","key":"2348_CR42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"16","key":"2348_CR43","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"key":"2348_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/cdr\/6345873","volume":"2026","author":"S Wang","year":"2026","unstructured":"Wang S, Li C, Fan D. The efficacy and safety of four novel PCSK9 monoclonal antibodies in patients with hypercholesterolemia: a systematic review with network meta-analysis and trial sequential analysis. Cardiovasc Ther. 2026;2026:6345873.","journal-title":"Cardiovasc Ther"},{"issue":"3","key":"2348_CR45","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389\u201395.","journal-title":"Drugs"},{"issue":"16","key":"2348_CR46","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"2348_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/jama.2025.20620","volume":"335","author":"CM Ballantyne","year":"2026","unstructured":"Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, et al. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA. 2026;335(2):129\u201339.","journal-title":"JAMA"},{"issue":"6","key":"2348_CR48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMoa2511002","volume":"394","author":"AM Navar","year":"2026","unstructured":"Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, et al. A placebo-controlled trial of the oral PCSK9 inhibitor Enlicitide. N Engl J Med. 2026;394(6):529\u201339.","journal-title":"N Engl J Med"},{"issue":"3","key":"2348_CR49","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee RG, Mazzola AM, Braun MC, Platt C, Vafai SB, Kathiresan S, et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation. 2023;147(3):242\u201353.","journal-title":"Circulation"},{"issue":"2","key":"2348_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100497","volume":"65","author":"MM Vroom","year":"2024","unstructured":"Vroom MM, Lu H, Lewis M, Thibodeaux BA, Brooks JK, Longo MS, et al. VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys. J Lipid Res. 2024;65(2):100497.","journal-title":"J Lipid Res"},{"issue":"4","key":"2348_CR51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.288.4.455","volume":"288","author":"JS Benner","year":"2002","unstructured":"Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455\u201361.","journal-title":"JAMA"},{"issue":"11","key":"2348_CR52","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMoa2208275","volume":"387","author":"JM Castellano","year":"2022","unstructured":"Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387(11):967\u201377.","journal-title":"N Engl J Med"},{"issue":"10355","key":"2348_CR53","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","volume":"400","author":"Cholesterol Treatment Trialists C","year":"2022","unstructured":"Cholesterol Treatment Trialists C. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832\u201345.","journal-title":"Lancet"},{"issue":"6","key":"2348_CR54","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","volume":"113","author":"W Koenig","year":"2024","unstructured":"Koenig W, Lorenz ES, Beier L, Gouni-Berthold I. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Clin Res Cardiol. 2024;113(6):812\u201321.","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"2348_CR55","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s12325-024-02868-z","volume":"41","author":"P Muntner","year":"2024","unstructured":"Muntner P, Ghazi L, Jones J, Dhalwani N, Poudel B, Wen Y, et al. Persistence and adherence to PCSK9 inhibitor monoclonal antibodies versus Ezetimibe in real-world settings. Adv Ther. 2024;41(6):2399\u2013413.","journal-title":"Adv Ther"},{"key":"2348_CR56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/VHRM.S180496","volume":"14","author":"DM Hines","year":"2018","unstructured":"Hines DM, Rane P, Patel J, Harrison DJ, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409\u201318.","journal-title":"Vasc Health Risk Manag"},{"key":"2348_CR57","doi-asserted-by":"crossref","unstructured":"Elis A, Melzer Cohen C, Chodick G. Real-world use of alirocumab: experience from a large healthcare provider. J Clin Med. 2023;12(3):1084.","DOI":"10.3390\/jcm12031084"},{"issue":"2","key":"2348_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5551\/jat.64848","volume":"32","author":"Y Takahashi","year":"2025","unstructured":"Takahashi Y, Morimoto T, Iekushi K, Arai H. A medical claims database study of factors associated with medication adherence and treatment persistence in patients receiving PCSK9 monoclonal antibodies. J Atheroscler Thromb. 2025;32(2):163\u201375.","journal-title":"J Atheroscler Thromb"},{"key":"2348_CR59","doi-asserted-by":"crossref","unstructured":"Svensson MK, James S, Ravn-Fischer A, Villa G, Schalin L, Cars T, et al. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels. Ups J Med Sci. 2024;129: e9618.","DOI":"10.48101\/ujms.v129.9618"},{"issue":"5","key":"2348_CR60","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"issue":"Suppl 1(Suppl 1","key":"2348_CR61","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.ihj.2024.01.006","volume":"76","author":"A Mehta","year":"2024","unstructured":"Mehta A. Non adherence to lipid-lowering therapy and strategies to improve adherence. Indian Heart J. 2024;76(Suppl 1(Suppl 1)):S138\u201340.","journal-title":"Indian Heart J"},{"issue":"6","key":"2348_CR62","first-page":"280","volume":"35","author":"AA Garcia-Pena","year":"2023","unstructured":"Garcia-Pena AA, Pineda-Posada M, Paez-Canro C, Cruz C, Samaca-Samaca D. Analysis of the evolocumab (Repatha(R)) patient support program for patients with cardiovascular disease in Colombia. Clin Investig Arterioscler. 2023;35(6):280\u20139.","journal-title":"Clin Investig Arterioscler"},{"issue":"2","key":"2348_CR63","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40261-019-00877-3","volume":"40","author":"C Piccinni","year":"2020","unstructured":"Piccinni C, Antonazzo IC, Maggioni AP, Pedrini A, Calabria S, Ronconi G, et al. PCSK9 inhibitors\u2019 new users: analysis of prescription patterns and patients\u2019 characteristics from an Italian real-world study. Clin Drug Investig. 2020;40(2):173\u201381.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"2348_CR64","first-page":"1098","volume":"10","author":"BJ Booth","year":"2018","unstructured":"Booth BJ, Ramakrishnan B, Narayan K, Wollacott AM, Babcock GJ, Shriver Z, et al. Extending human IgG half-life using structure-guided design. MAbs. 2018;10(7):1098\u2013110.","journal-title":"MAbs"},{"issue":"9","key":"2348_CR65","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715\u201325.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2348_CR66","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","volume":"289","author":"V Oganesyan","year":"2014","unstructured":"Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem. 2014;289(11):7812\u201324.","journal-title":"J Biol Chem"},{"issue":"16","key":"2348_CR67","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMra2312718","volume":"392","author":"JB Bussel","year":"2025","unstructured":"Bussel JB, Cines DB, Blumberg RS. Neonatal Fc receptor - biology and therapeutics. N Engl J Med. 2025;392(16):1621\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"2348_CR68","first-page":"311","volume":"9","author":"M Malkinson","year":"1965","unstructured":"Malkinson M. The transmission of passive immunity to Escherichia coli from mother to young in the domestic fowl (Gallus domesticus). Immunology. 1965;9(4):311\u20137.","journal-title":"Immunology"},{"issue":"7","key":"2348_CR69","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1172\/JCI6968","volume":"104","author":"BL Dickinson","year":"1999","unstructured":"Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest. 1999;104(7):903\u201311.","journal-title":"J Clin Invest"},{"issue":"7","key":"2348_CR70","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023;23(7):415\u201332.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2348_CR71","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6","volume":"29","author":"JK Kim","year":"1999","unstructured":"Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol. 1999;29(9):2819\u201325.","journal-title":"Eur J Immunol"},{"issue":"1","key":"2348_CR72","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","volume":"9","author":"A Grevys","year":"2018","unstructured":"Grevys A, Nilsen J, Sand KMK, Daba MB, Oynebraten I, Bern M, et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat Commun. 2018;9(1):621.","journal-title":"Nat Commun"},{"issue":"14","key":"2348_CR73","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1073\/pnas.0700337104","volume":"104","author":"P Prabhat","year":"2007","unstructured":"Prabhat P, Gan Z, Chao J, Ram S, Vaccaro C, Gibbons S, et al. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci USA. 2007;104(14):5889\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2348_CR74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0969-2126(98)00008-2","volume":"6","author":"DE Vaughn","year":"1998","unstructured":"Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure. 1998;6(1):63\u201373.","journal-title":"Structure"},{"issue":"4","key":"2348_CR75","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1097-2765(01)00230-1","volume":"7","author":"WL Martin","year":"2001","unstructured":"Martin WL, West AP Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn\/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001;7(4):867\u201377.","journal-title":"Mol Cell"},{"issue":"33","key":"2348_CR76","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall'Acqua","year":"2006","unstructured":"Dall\u2019Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514\u201324.","journal-title":"J Biol Chem"},{"issue":"9","key":"2348_CR77","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"2348_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12916-021-02208-w","volume":"20","author":"M Xu","year":"2022","unstructured":"Xu M, Zhu X, Wu J, Zhang Y, Zhao D, Wang X, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study. BMC Med. 2022;20(1):13.","journal-title":"BMC Med"},{"key":"2348_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01512-5","author":"C Shu","year":"2025","unstructured":"Shu C, Wang Y, Feng S, Yang S, Shen K. Population pharmacokinetics and pharmacodynamics modeling for the use of Recaticimab in healthy volunteers and patients with hypercholesterolemia. Clin Pharmacokinet. 2025;64(9):1341-55.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2348_CR80","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s13318-025-00944-5","volume":"50","author":"Y Wang","year":"2025","unstructured":"Wang Y, Cheng Y, Guo Y, Fan Y, Zhou R, Zhang Q, et al. A phase I study to evaluate the relative bioavailability, pharmacodynamics, and safety of a single subcutaneous injection of recaticimab at three different sites in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2025;50(3):265\u201372.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2348_CR81","doi-asserted-by":"crossref","unstructured":"Sun Y, Chen ZY. Immunogenicity of recaticimab does not impact its efficacy in patients with dyslipidemia: a pooled analysis of three phase III and one phase Ib\/II studies. 2025; 152(Suppl_3): A4368112.","DOI":"10.1161\/circ.152.suppl_3.4368112"},{"issue":"16","key":"2348_CR82","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376(16):1517\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"2348_CR83","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cvr\/cvaf155","volume":"121","author":"L Li","year":"2025","unstructured":"Li L, Zhou Y, Deng C, Sheng J, Peng D, Ling Z, et al. Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled phase 3 study. Cardiovasc Res. 2025;121(12):1856\u201364.","journal-title":"Cardiovasc Res"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02348-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02348-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02348-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:02:26Z","timestamp":1784203346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02348-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2348"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02348-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jian-Jun Li conceived, designed, and programmed the paper, Sha Li and Ying Gao wrote the manuscript and Cheng-Gang Zhu reviewed, revised, and finalized the manuscript. All authors have read and approved the final version.","order":2,"name":"Ethics","label":"Authors' contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing not applicable to this article as no datasets were generated for this review article.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}